Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Monday 08 February, 2010

Lipoxen PLC

Patent Granted

RNS Number : 7796G
Lipoxen PLC
08 February 2010

For immediate release

8 February 2010




Lipoxen plc

('Lipoxen' or 'the Company')


Lipoxen's Polysialylated G-CSF StimuXen Technology

Granted European Patent



Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces that it has been granted patents for its Polysialylated G-CSF StimuXen Technology in six European territories, including the UK, Germany, France, Spain, Italy and Switzerland.


This technology is based on polysialic acid (PSA, a polymer occurring naturally in humans), which extends a protein's active life. PSA is biodegradable, non-immunogenic and non-toxic and is also therefore expected to avoid the toxicity attributed to polyethylene glycol (PEG) in PEGylated protein drug candidates. 


StimuXen uses Lipoxen's patented PolyXen technology to attach polysialic acid onto the N-terminal of G-CSF to produce polysialylated G-CSF. The patent application related to it is recent and has now been granted in Europe. Preclinical work with StimuXen has shown improved pharmacokinetics and pharmacodynamics which are similar to those of the longest-acting version of G-CSF on the market whose patent expires in 2015. G-CSF generated global sales of $5.2B in 2008.


How it works


The G-CSF (granulocyte-colony stimulating factor) stimulates the bone marrow to produce more white blood cells (WBC).


A major side effect of chemotherapy is a reduction in the number of WBC which can lead to a patient's reduced ability to fight infection, consequent to which chemotherapy may be postponed or the dose lowered, neither outcome being optimal for the preferred treatment. Prescription of G-CSF acts to protect the body's level of WBC during chemotherapy and is usually administered daily for up to 14 days.


The leading currently available G-CSF therapy is administered once with each cycle of chemotherapy. Lipoxen expects that the improved StimuXen G-CSF will have a similar treatment profile.


Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "We are confident that StimuXen™, which is currently in pre-clinical development, could be as successful as our two potential billion dollar block-buster products in clinical development, SuliXen™, a long acting insulin, and ErepoXen™, a long-acting erythropoietin (EPO) both of which are based on this PolyXen™ technology."


- Ends -


For further information please contact:


Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating, Claes Spång

Noble & Company

+44 (0)20 7763 2200

James Bromhead, Sam Reynolds   

Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Catherine Breen


Notes for Editors


About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:


1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA


Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 


Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for Factor VIII


The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009.


Lipoxen, which was founded in 1997, now trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website:


This information is provided by RNS
The company news service from the London Stock Exchange